- Home
- IBRX vs WLY Comparison
IBRX vs WLY Comparison
Compare IBRX & WLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- WLY
- Stock Information
- Founded
- IBRX 2014
- WLY 1807
- Country
- IBRX United States
- WLY United States
- Employees
- IBRX N/A
- WLY N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- WLY Books
- Sector
- IBRX Health Care
- WLY Consumer Discretionary
- Exchange
- IBRX Nasdaq
- WLY Nasdaq
- Market Cap
- IBRX 2.3B
- WLY 2.1B
- IPO Year
- IBRX N/A
- WLY N/A
- Fundamental
- Price
- IBRX $2.81
- WLY $42.58
- Analyst Decision
- IBRX Strong Buy
- WLY
- Analyst Count
- IBRX 5
- WLY 0
- Target Price
- IBRX $11.40
- WLY N/A
- AVG Volume (30 Days)
- IBRX 7.3M
- WLY 774.6K
- Earning Date
- IBRX 08-11-2025
- WLY 09-04-2025
- Dividend Yield
- IBRX N/A
- WLY 3.24%
- EPS Growth
- IBRX N/A
- WLY N/A
- EPS
- IBRX N/A
- WLY 1.53
- Revenue
- IBRX $31,222,000.00
- WLY $1,677,609,000.00
- Revenue This Year
- IBRX $567.98
- WLY $1.75
- Revenue Next Year
- IBRX $160.56
- WLY $2.40
- P/E Ratio
- IBRX N/A
- WLY $27.82
- Revenue Growth
- IBRX 10238.41
- WLY N/A
- 52 Week Low
- IBRX $1.83
- WLY $36.50
- 52 Week High
- IBRX $7.48
- WLY $53.96
- Technical
- Relative Strength Index (RSI)
- IBRX 51.33
- WLY 51.26
- Support Level
- IBRX $2.68
- WLY $41.48
- Resistance Level
- IBRX $3.00
- WLY $43.97
- Average True Range (ATR)
- IBRX 0.16
- WLY 1.00
- MACD
- IBRX -0.00
- WLY -0.05
- Stochastic Oscillator
- IBRX 62.00
- WLY 26.44
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.